Shareholder Alert: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Hutchmed (China) Limited - HCM

New York, New York--(Newsfile Corp. - May 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of HUTCHMED (China) Limited ("Hutchmed" or the "Company") (NASDAQ: HCM). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Hutchmed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On May 2, 2022, Hutchmed announced that the U.S. Food and Drug Administration ("FDA") rejected Hutchmed's application seeking approval of surufatinib to treat certain neuroendocrine tumors, noting that the data submitted did not support an approval and a multi-regional clinical trial is required.

On this news, Hutchmed's stock price fell $2.86 per share, or 18.95%, to close at $12.23 per share on May 2, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125697